Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 31c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 31c, Revenues Miss

Eagle Pharmaceuticals Reports Third Quarter 2019 Results

November 12, 2019 6:51 AM EST

-- Net loss of $0.17 per basic and diluted share and adjusted non-GAAP net income of $0.27 per basic and $0.26 per diluted share in Q3 2019 --

-- Plan to initiate a clinical trial in December for Eagles innovative fulvestrant program, which has the potential to result in greater inhibition of estrogen receptors and better outcomes for patients with estrogen receptor-positive breast cancer --

-- Company returned to 2019 Hajj and enrolled additional EHS patients in its controlled clinical study --

-- Eagle expects to file a... More